Cogent Biosciences, Inc.
COGT
Price:
$10.47
Market Cap:
$1.15B
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 a...[Read more]
Industry
Biotechnology
IPO Date
2018-03-29
Stock Exchange
NASDAQ
Ticker
COGT
The ROE as of September 2024 (TTM) for Cogent Biosciences, Inc. (COGT) is -66.96%
According to Cogent Biosciences, Inc.’s latest financial reports and current stock price. The company's current ROE is -66.96%. This represents a change of 288.29% compared to the average of -17.25% of the last 4 quarters.
Cogent Biosciences, Inc. (COGT) Historical ROE (quarterly & annually)
How has COGT ROE performed in the past?
The mean historical ROE of Cogent Biosciences, Inc. over the last ten years is -52.79%. The current -66.96% ROE has changed 26.84% with respect to the historical average. Over the past ten years (40 quarters), COGT's ROE was at its highest in in the September 2020 quarter at 225.41%. The ROE was at its lowest in in the March 2018 quarter at -42.36%.
Average
-52.79%
Median
-51.87%
Minimum
-95.31%
Maximum
-9.48%
Cogent Biosciences, Inc. (COGT) ROE by Quarter and Year
Discovering the peaks and valleys of Cogent Biosciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 264.85%
Maximum Annual ROE = -9.48%
Minimum Annual Increase = -70.29%
Minimum Annual ROE = -95.31%
| Year | ROE | Change |
|---|---|---|
| 2023 | -74.63% | 43.90% |
| 2022 | -51.87% | 54.71% |
| 2021 | -33.53% | 18.39% |
| 2020 | -28.32% | -70.29% |
| 2019 | -95.31% | 66.25% |
| 2018 | -57.33% | -36.34% |
| 2017 | -90.06% | 160.33% |
| 2016 | -34.60% | 264.85% |
Cogent Biosciences, Inc. (COGT) Average ROE
How has COGT ROE performed in the past?
The current ROE of Cogent Biosciences, Inc. (COGT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-53.34%
5-year avg
-56.73%
10-year avg
-52.79%
Cogent Biosciences, Inc. (COGT) ROE vs. Peers
How is COGT’s ROE compared to its peers?
Cogent Biosciences, Inc.’s ROE is greater than Larimar Therapeutics, Inc. (-37.84%), greater than Kura Oncology, Inc. (-40.43%), greater than Kiniksa Pharmaceuticals, Ltd. (-5.10%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than IDEAYA Biosciences, Inc. (-20.53%), greater than AnaptysBio, Inc. (-255.67%), greater than MeiraGTx Holdings plc (-86.28%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Homology Medicines, Inc. (-100.91%), greater than Sana Biotechnology, Inc. (-71.60%), greater than Olema Pharmaceuticals, Inc. (-44.18%), greater than Cullinan Oncology, Inc. (-28.37%), greater than aTyr Pharma, Inc. (-56.83%), greater than Zentalis Pharmaceuticals, Inc. (-44.23%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), greater than KalVista Pharmaceuticals, Inc. (-97.37%), greater than Mersana Therapeutics, Inc. (-333.91%), greater than Ventyx Biosciences, Inc. (-61.43%), less than Protagonist Therapeutics, Inc. (85.47%), greater than Verona Pharma plc (-55.46%),
| Company | ROE | Market cap |
|---|---|---|
| -37.84% | $513.64M | |
| -40.43% | $1.48B | |
| -5.10% | $1.78B | |
| -98.94% | $8.19B | |
| -20.53% | $3.06B | |
| -255.67% | $1.08B | |
| -86.28% | $300.31M | |
| -44.73% | $1.97B | |
| -100.91% | $3.02M | |
| -71.60% | $1.12B | |
| -44.18% | $677.46M | |
| -28.37% | $1.04B | |
| -56.83% | $131.12M | |
| -44.23% | $210.48M | |
| -57.42% | $1.63B | |
| -97.37% | $531.63M | |
| -333.91% | $165.61M | |
| -61.43% | $153.35M | |
| 85.47% | $2.44B | |
| -55.46% | $2.14B |
Build a custom stock screener for Cogent Biosciences, Inc. (COGT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cogent Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Cogent Biosciences, Inc. (COGT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Cogent Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Cogent Biosciences, Inc.'s ROE?
How is the ROE calculated for Cogent Biosciences, Inc. (COGT)?
What is the highest ROE for Cogent Biosciences, Inc. (COGT)?
What is the 3-year average ROE for Cogent Biosciences, Inc. (COGT)?
What is the 5-year average ROE for Cogent Biosciences, Inc. (COGT)?
How does the current ROE for Cogent Biosciences, Inc. (COGT) compare to its historical average?